HemaSphere (Jun 2022)
P674: UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
- C. Ryan,
- D. Brander,
- P. Barr,
- S. Tyekucheva,
- Y. Ren,
- L. Hackett,
- M. McDonough,
- K. Pena Del Aguila,
- M. McEwan,
- M. Collins,
- J. Abramson,
- E. Jacobsen,
- A. LaCasce,
- D. Fisher,
- J. Brown,
- M. Davids
Affiliations
- C. Ryan
- 1 Medical Oncology, Dana-Farber Cancer Institute, Boston
- D. Brander
- 2 Duke University Cancer Center, Durham
- P. Barr
- 3 University of Rochester Wilmot Cancer Institute, Rochester
- S. Tyekucheva
- 4 Data Science, Dana-Farber Cancer Institute, Boston, United States of America
- Y. Ren
- 4 Data Science, Dana-Farber Cancer Institute, Boston, United States of America
- L. Hackett
- 1 Medical Oncology, Dana-Farber Cancer Institute, Boston
- M. McDonough
- 1 Medical Oncology, Dana-Farber Cancer Institute, Boston
- K. Pena Del Aguila
- 1 Medical Oncology, Dana-Farber Cancer Institute, Boston
- M. McEwan
- 1 Medical Oncology, Dana-Farber Cancer Institute, Boston
- M. Collins
- 1 Medical Oncology, Dana-Farber Cancer Institute, Boston
- J. Abramson
- 1 Medical Oncology, Dana-Farber Cancer Institute, Boston
- E. Jacobsen
- 1 Medical Oncology, Dana-Farber Cancer Institute, Boston
- A. LaCasce
- 1 Medical Oncology, Dana-Farber Cancer Institute, Boston
- D. Fisher
- 1 Medical Oncology, Dana-Farber Cancer Institute, Boston
- J. Brown
- 1 Medical Oncology, Dana-Farber Cancer Institute, Boston
- M. Davids
- 1 Medical Oncology, Dana-Farber Cancer Institute, Boston
- DOI
- https://doi.org/10.1097/01.HS9.0000845580.45096.48
- Journal volume & issue
-
Vol. 6
pp. 572 – 573
Abstract
No abstracts available.